Diseases [C] » Musculoskeletal Diseases [C05] » Bone Diseases » Spinal Diseases » Spondylitis » Spondylarthritis » Spondylarthropathies » Axial Spondyloarthritis
Diseases [C] » Musculoskeletal Diseases [C05] » Joint Diseases » Ankylosis » Axial Spondyloarthritis
Diseases [C] » Musculoskeletal Diseases [C05] » Joint Diseases » Arthritis » Spondylarthritis » Spondylarthropathies » Axial Spondyloarthritis
Description
A spectrum of chronic inflammatory conditions affecting the axial joints (e.g., SPINE), characterized by pain, stiffness of joints (ANKYLOSIS), reduced mobility and inflammation. When joint inflammation and damage are visible on regular X-rays it is called ANKYLOSING SPONDYLITIS; otherwise it is referred to as NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. HLA-B27 ANTIGEN is a biomarker and IL-23/IL-17 pathway a potential therapeutic target for axial and other related spondyloarthritis. MeSH
Hierarchy View
Subtype Terms (2)
Non-Radiographic Axial Spondyloarthritis
5 drugs (3 approved, 2 experimental)
Spondylitis, Ankylosing
92 drugs (57 approved, 35 experimental)
Phase 4 Indicated Drugs (19)
Phase 2 Indicated Drugs (5)
Phase 1 Indicated Drugs (1)
Other Experimental Indicated Drugs (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
